Adverse effects of β-agonists: Are they clinically relevant?

American Journal of Respiratory Medicine

Volumn 2, Issue 4, 2003, Pages 287-297

  Abramson, Michael J ^a   Walters, Julia ^b   Walters, E Haydn ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BAMBUTEROL; BECLOMETASONE; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHOCONSTRICTING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; ISOPRENALINE; LONG ACTING DRUG; METHACHOLINE; NEDOCROMIL; ORCIPRENALINE; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG SAFETY; DRUG SELECTIVITY; GENOTYPE; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; HYPOKALEMIA; HYPOXIA; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; NEBULIZATION; OBSTRUCTIVE AIRWAY DISEASE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TACHYCARDIA; TACHYPHYLAXIS; TREMOR;

EID: 0041885456     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256657     Document Type: Review

References (55)

1. Burney P, Chinn D, Luczynska C, et al. Variations in the prevalence of respiratory, symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9 (4): 687-95
2. ISAAC. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12 (2): 315-35
3. Janson C, Chinn S, Jarvis D, et al. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10 (8): 1795-802
4. Wong CS, Pavord I, Williams J, et al. Bronchodilator, cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396-9
5. Neville A, Palmer JB, Gaddie J, et al. Metabolic effects of salbutamol: comparison of aerosol and intravenous administration. BMJ 1977; 1 (6058): 413-4
6. Burggraaf J, Westendorp RG, in't Veen JC, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56 (7): 567-9
7. Williams AJ, Weiner C, Reiff D, et al. Comparison of the effect of inhaled selective and non-selective adrenergic agonists on cardiorespiratory parameters in chronic stable asthma. Pulm Pharmacol 1994; 7 (4): 235-41
8. Walters E, Cockroft A, Griffiths T, et al. Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels. Thorax 1981; 36: 625-58
9. Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001; 24 (14): 1065-80
10. Pearce N, Beasley R, Crane J, et al. End of the New Zealand asthma mortality epidemic. Lancet 1995; 345 (8941): 41-4
11. Suissa S, Ernst P. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic. J Clin Epidemiol 1997; 50 (10): 1079-88
12. Lanes SF, Birmann B, Raiford D, et al. International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992. J Clin Epidemiol 1997; 50 (3): 321-8
13. Romano F, Recchia G, Staniscia T, et al. Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994. Eur J Epidemiol 2000; 16 (9): 783-7
14. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989; 1 (8644): 917-22
15. Crane J, Pearce N, Burgess C, et al. Asthma and the beta agonist debate. Thorax 1995; 50 Suppl. 1: S5-10
16. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45 (3): 170-5
17. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46 (2): 105-11
18. Spitzer WO, Suissa S, Ernst P, et al. The use of beta agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-6
19. Suissa S, Ernst P, Bolvin JF. A cohort analysis of excess mortality in asthma and the use of inhaled beta agonists. Am J Respir Crit Care Med 1994; 149: 604-10
20. Abramson M, Bailey M, Couper F, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001; 163 (1): 12-8
21. Rea HH, Scragg R, Jackson R, et al. A case-control study of deaths from asthma. Thorax 1986; 41 (11): 833-9
22. Beasley R, Burgess C, Pearce N, et al. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 1994; 24 (7): 660-8
23. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996; 144 (12): 1161-9
24. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268 (24): 3462-4
25. Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49 (2): 247-50
26. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52 (7): 612-7
27. Campbell DA, McLennan G, Coates JR, et al. A comparison of asthma deaths and near-fatal asthma attacks in South Australia. Eur Respir J 1994; 7 (3): 490-7
28. Garrett JE, Lanes SF, Kolbe J, et al. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax 1996; 51 (11): 1093-9
29. Pearce N, Hensley MJ. Epidemiologic studies of beta agonists and asthma deaths. Epidemiol Rev 1998; 20 (2): 173-86
30. Van Ganse E, van der Linden PD, Leufkens HG, et al. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8 (11): 1856-60
31. Van der Merwe L, Plaatjes M, Van Schalwyk E, et al. Risk factors for near-fatal and fatal asthma in a third world population [abstract]. Respirology 2002; 7 Suppl.: A26
32. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53 (1): 7-13
33. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154 (6 Pt 1): 1598-602
34. Martin RM, Dunn NR, Freemantle SN, et al. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 1998; 53 (7): 558-62
35. Au DH, Curtis JR, Psaty BM. Risk of myocardial ischaemia and beta-adrenoceptor agonists. Ann Med 2001; 33 (5): 287-90
36. Holgate ST, Baldwin CJ, Tattersfield AE. Beta-adrenergic agonist resistance in normal human airways. Lancet 1977; II (8034): 375-7
37. Harvey JE, Baldwin CJ, Wood PJ, et al. Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. Clin Sci (Lond) 1981; 60 (5): 579-85
38. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6
39. Newnham D, Grove A, McDevitt D, et al. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 475-504
40. O'Connor BJ, Fuller RW, Barnes PJ. Nonbronchodilator effects of inhaled beta 2 agonists: greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1994; 150 (2): 381-7
41. Beach JR, Young CL, Harkawat R, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155-7
42. Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996; 51: 1100-4
43. Cockcroft DW, Swystun VA. Functional antagonism produced by inhaled beta agonists. Thorax 1996; 51: 1051-6
44. Aldridge RE, Hancox RJ, Robin Taylor D, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000; 161 (5): 1459-64
45. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-30
46. Page CP. An explanation of the asthma paradox. Am Rev Resp Dis 1993; 147: S29-33
47. Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting beta2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-9
48. Walters EH, Bjermer L, Faurschou P, et al. The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients. Respir Med 2000; 94 Suppl. F: S26-31
49. Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159 (1): 79-86
50. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274 (2): 1005-10
51. 2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164 (1): 117-21
52. Walters EH, Walters JA. A genetic twist to the beta-agonist 'debate'. Clin Sci (Lond) 1999; 96 (3): 219-20
53. Walters E, Walters J. Inhaled short acting beta-2 agonist use in asthma: regular versus as-needed treatment. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue. Oxford: Oxford Update Software, 2000; Issue 3
54. Walters EH, Walters JA, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta-agoinists in adults and children with stable asthma. Cochrane Database Syst Rev 2003; (1)
55. Wooltorton E. Salmeterol (Severent) asthma trial halted early. CMAJ 2003; 168 (6): 738